AR008559A1 - Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo - Google Patents
Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismoInfo
- Publication number
- AR008559A1 AR008559A1 ARP980101391A ARP980101391A AR008559A1 AR 008559 A1 AR008559 A1 AR 008559A1 AR P980101391 A ARP980101391 A AR P980101391A AR P980101391 A ARP980101391 A AR P980101391A AR 008559 A1 AR008559 A1 AR 008559A1
- Authority
- AR
- Argentina
- Prior art keywords
- pps
- pharmaceutically acceptable
- acceptable salt
- pentosanpolysulfate
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uso de pentosanpolisulfato (PPS) o de una sal farmacéuticamente aceptable del mismo, para preparar una composicion farmacéutica util para eltratamiento de un paciente mamífero que sufre una enfermedad cicatrizante vascular progresiva cronica(CPVD), particularmente una enfermedadarterioesclerotica como la aterioesclerosis, que tiene por objeto detener el progreso de la misma y causar la resolucion o disminucion de las lesionesy cicatrices ya formadas. De acuerdo a dichotratamiento se administra al paciente una composicion farmacéutica que contiene una cantidad efectiva depentosanpolisulfato (PPS) o de una sal farmacéuticamente aceptable del mismo. Se prefiere la vía oral de administracion, oscilandola dosis di ariatotal de PPS o sal de PPS aproximadamente entre 5 y 30 mg/kg. de peso, o aproximadamente entre 350 y 2000 mg en pacientes humanos adultos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/840,777 US20010005720A1 (en) | 1995-06-07 | 1997-04-16 | Method of treating chronic progressive vascular scarring diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008559A1 true AR008559A1 (es) | 2000-01-19 |
Family
ID=25283204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101391A AR008559A1 (es) | 1997-04-16 | 1998-03-26 | Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20010005720A1 (es) |
| EP (1) | EP0986392A4 (es) |
| JP (1) | JPH1149802A (es) |
| KR (1) | KR20010006511A (es) |
| CN (1) | CN1259871A (es) |
| AR (1) | AR008559A1 (es) |
| AU (1) | AU750182B2 (es) |
| BR (1) | BR9809396A (es) |
| CA (1) | CA2285950A1 (es) |
| HU (1) | HUP0003256A3 (es) |
| IL (1) | IL132389A0 (es) |
| NO (1) | NO995024L (es) |
| NZ (1) | NZ500527A (es) |
| SK (1) | SK142599A3 (es) |
| TW (1) | TW557213B (es) |
| WO (1) | WO1998046237A1 (es) |
| ZA (1) | ZA982246B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005292202A1 (en) * | 2004-10-01 | 2006-04-13 | Keryx Biopharmaceuticals, Inc. | Methods using glycosaminoglycans for the treatment of kidney disease |
| EP2407174B1 (en) | 2009-03-11 | 2014-05-07 | Jellice Co., Ltd. | Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses |
| CN102327282A (zh) * | 2010-09-01 | 2012-01-25 | 吴洪 | 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途 |
| JP6225321B1 (ja) | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
| BR112020003908B1 (pt) | 2016-08-31 | 2023-01-24 | Oji Holdings Corporation | Método para produzir um ingrediente farmacêutico ativo incluindo polissulfato de pentosano |
| JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
| BR112019025030A2 (pt) | 2017-05-31 | 2020-06-16 | Oji Holdings Corporation | Preparação umidificante tópica. |
| AU2018333249B2 (en) | 2017-09-12 | 2023-03-02 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
| MX2020006605A (es) | 2017-12-20 | 2020-09-10 | Oji Holdings Corp | Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano. |
| WO2023070164A1 (en) * | 2021-10-28 | 2023-05-04 | Paradigm Biopharmaceuticals Ltd | Treatment of heart failure with preserved ejection fraction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820693A (en) * | 1986-05-22 | 1989-04-11 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
| US5643892A (en) * | 1995-06-07 | 1997-07-01 | Baker Norton Pharmaceuticals, Inc. | Method of treating chronic progressive vascular diseases |
-
1997
- 1997-04-16 US US08/840,777 patent/US20010005720A1/en not_active Abandoned
-
1998
- 1998-03-17 ZA ZA982246A patent/ZA982246B/xx unknown
- 1998-03-26 AR ARP980101391A patent/AR008559A1/es unknown
- 1998-04-02 JP JP10108762A patent/JPH1149802A/ja active Pending
- 1998-04-10 KR KR1019997009601A patent/KR20010006511A/ko not_active Application Discontinuation
- 1998-04-10 NZ NZ500527A patent/NZ500527A/en unknown
- 1998-04-10 CA CA002285950A patent/CA2285950A1/en not_active Abandoned
- 1998-04-10 SK SK1425-99A patent/SK142599A3/sk unknown
- 1998-04-10 IL IL13238998A patent/IL132389A0/xx unknown
- 1998-04-10 CN CN98805235A patent/CN1259871A/zh active Pending
- 1998-04-10 AU AU72482/98A patent/AU750182B2/en not_active Ceased
- 1998-04-10 WO PCT/US1998/007517 patent/WO1998046237A1/en not_active Application Discontinuation
- 1998-04-10 BR BR9809396-7A patent/BR9809396A/pt unknown
- 1998-04-10 HU HU0003256A patent/HUP0003256A3/hu unknown
- 1998-04-10 EP EP98919769A patent/EP0986392A4/en not_active Withdrawn
- 1998-04-15 TW TW087105754A patent/TW557213B/zh active
-
1999
- 1999-10-15 NO NO995024A patent/NO995024L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998046237A1 (en) | 1998-10-22 |
| TW557213B (en) | 2003-10-11 |
| AU7248298A (en) | 1998-11-11 |
| AU750182B2 (en) | 2002-07-11 |
| HUP0003256A2 (hu) | 2001-02-28 |
| IL132389A0 (en) | 2001-03-19 |
| HUP0003256A3 (en) | 2001-12-28 |
| CA2285950A1 (en) | 1998-10-22 |
| BR9809396A (pt) | 2000-06-13 |
| EP0986392A4 (en) | 2000-04-26 |
| KR20010006511A (ko) | 2001-01-26 |
| NZ500527A (en) | 2001-10-26 |
| US20010005720A1 (en) | 2001-06-28 |
| CN1259871A (zh) | 2000-07-12 |
| NO995024L (no) | 1999-12-13 |
| NO995024D0 (no) | 1999-10-15 |
| JPH1149802A (ja) | 1999-02-23 |
| SK142599A3 (en) | 2001-12-03 |
| ZA982246B (en) | 1998-09-17 |
| EP0986392A1 (en) | 2000-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
| BR9909192A (pt) | Preparações galênicas de meloxicam para administração oral | |
| ES2170069T3 (es) | 1-alfa-hidroxiprevitamina d para administracion oral. | |
| ES2171469T3 (es) | Composicion administrada por via nasal y preparacion que la contiene. | |
| ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
| BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| BR9306841A (pt) | Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico | |
| BRPI0108435B8 (pt) | formulação e uso de entecavir de baixa dose | |
| KR960700061A (ko) | 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence) | |
| AR008559A1 (es) | Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo | |
| ES2171440T3 (es) | Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal. | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| AR019053A1 (es) | Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen | |
| ATE257704T1 (de) | Pharmazeutische zusammensetzungen enthaltend norastemizol. | |
| CL2004000304A1 (es) | Uso del acido 4-[1-hidroxi-4-[4-hidroxidifenilmetil)-1-piperidinil]butil]-alfa, alfa-dimetilbenceno acetico o una sal farmaceuticamente aceptable del mismo, para la preparacion de un medicamento util como antihistaminico, en pacientes que padecen un | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| GB9023701D0 (en) | Medical treatment | |
| KR970705402A (ko) | 발작과 심근경색에서 대식세포의 침윤과 연관된 질병과 질환의 치료(treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction) | |
| KR890004705A (ko) | 항바이러스성 제제 | |
| AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |